Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.
Journal: JAMA dermatology
Published: June 15, 2017
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.
Journal: World journal of virology
Published: June 11, 2017
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.
Journal: World journal of hepatology
Published: June 22, 2015
Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Journal: Molecular medicine (Cambridge, Mass.)
Published: May 01, 2015
Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
Journal: The Journal of infectious diseases
Published: June 28, 2014
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: May 20, 2013
Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.
Journal: Molecular medicine (Cambridge, Mass.)
Published: November 30, 2012
Long-term care of the liver transplant recipient.
Journal: Clinics in liver disease
Published: July 04, 2007
Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation.
Journal: Expert review of clinical immunology
Published: March 01, 2007
Showing 1-10 of 10
Last Updated: 09/26/2026